The RSI oscillates between zero and 100. (NASDAQ:SGYP) shares tanked -3.36% to $4.32 on Wednesday.
When it comes to the Analysis of a Stock, Price Target plays a vital role. It represents a security's price that, if achieved, results in a trader recognizing the best possible outcome for his investment. If faced, it would be a -23.48% drop from its current position. It has been assigned a low target price of $1 and a high target price of $1. These price targets are a consensus analysis of 6 brokers. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.
According to Yahoo Finance, the price target for the company which analysts are aiming is 18. (SGYP) a rating of 1 on a scale of 1 to 5. Synergy Pharmaceuticals has a 12 month low of $2.62 and a 12 month high of $7.15. Noting its average daily volume at 2.01 million shares each day over the month, this signifies a pretty significant change over the norm.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP)'s average revenue estimates for the current quarter are $30K according to 3 number of analysts. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.11.
The company is expected to report earnings of $-0.19 a share for the next quarter. The count of Hold ratings in that period was 1. It is the "top line" or "gross income" figure from which costs are subtracted to determine net income.
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), maintained return on investment for the last twelve months at -253.37, higher than what Reuters data shows regarding industry's average. The stock stands almost $3.09 off versus the 52-week high of $7.15 and $1.44 above the 52-week low of $2.62. One of the most effective and widely used technical trading indicators is simple moving average. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. The average volume of a stock suggests the liquidity of a particular company.
The difference of 52 week low value as well as 52 week high value and the current price of the stock suggests the next move of the shares. If the share price is now hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. Oppenheimer Holdings Inc. set a $10.00 target price on Synergy Pharmaceuticals and gave the stock a "buy" rating in a research report on Saturday, January 21st.
Other research analysts have also recently issued research reports about the stock. Stock has got OUTPERFORM rating from 2 analysts of Thomson Reuters, 19 analysts given HOLD rating to the stock and 1 given UNDERPERFORM rating.
Another critical number in evaluating a stock is P/E or the price to earnings ratio. Paulson & CO. Inc. now owns 27,756,668 shares of the biopharmaceutical company's stock worth $105,475,000 after buying an additional 16,666,668 shares during the last quarter.
Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Canaccord Genuity also Initiated the company to Buy on 22-May-15, 2016. The stock has been given a Neutral rating.
A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future.
Delta cancels more flights after storm hits Atlanta
The airline's travel waiver has been extended into the weekend so that customers can rebook their flights without the change fee. Friday. "We now have 3 cancellations on the books for (Monday) and expect a relatively normal operational day", Thomas said.
Krejci scratched from Bruins' Game 1 lineup
Of their last 19 games, the Bruins have scored in 12 of their games, meaning that the Bruins' powerplay is on the upturn. It was a hard lesson to learn, but head coach Guy Boucher hopes it will be a lasting one for the Ottawa Senators.